Global News
Celltrion Secures Interchangeability Approval for Humira Biosimilar in the U.S.
Celltrion, a South Korean biopharmaceutical company, has received interchangeability approval for its biosimilar Yuflyma, intended for autoimmune diseases, from the U.S. FDA. This designation will…